SEC Filings TLDR Banner

Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.

Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.

Filter by Form Type:
All346-K8-K10-Q144Schedule 13GSchedule 13G/ASchedule 13DSchedule 13D/A
Industry:Biotechnologyβœ•
Previous Page1415161718192021Next Page
2026-05-15BYSISCHEDULE 13G/ABeyondSpring Inc. Co-Founders File Amendment No. 9 Reporting 14.1% Beneficial OwnershipMEDIUM
This Schedule 13G/A (Amendment No. 9) filed on May 15, 2026, reports the beneficial ownership of BeyondSpring Inc. (BYSI) by Co-founders Dr. Lan Huang and Mr. Linqing Jia. The filing indicates that Dr. Huang and Mr. Jia each beneficially own 5,787,906 ordinary shares, representing a 14.1% stake in the company based on ...
Micro CapBiotechnology
2026-05-15BCAXSCHEDULE 13G/AVestal Point Capital Reports 8.3% Stake in Bicara Therapeutics Inc. (BCAX)HIGH
Vestal Point Capital, LP, along with Mr. Ryan Wilder, filed a Schedule 13G/A on May 15, 2026, disclosing an 8.3% stake in Bicara Therapeutics Inc. (BCAX). The reporting persons beneficially own 5,425,000 shares of common stock, which were acquired in the ordinary course of business. This filing represents a significant...
Small CapBiotechnologyownership +8.30%
2026-05-15BCAXSCHEDULE 13G/ADeep Track Capital Increases Stake in Bicara Therapeutics to 6.21%MEDIUM
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Bicara Therapeutics Inc. (BCAX). The filing indicates that as of March 31, 2026, the reporting persons beneficially own 4,062,500 shares of Common Stock, rep...
Small CapBiotechnologyownership +6.21%
2026-05-15BNTXSCHEDULE 13G/AProf. Ugur Sahin and Medine GmbH Report 15.8% Stake in BioNTech SE (Amendment No. 6)HIGH
This Amendment No. 6 to Schedule 13G, filed on May 15, 2026, reports the beneficial ownership of BioNTech SE (BNTX) by Medine GmbH and Prof. Ugur Sahin, M.D. As of the event date of March 31, 2026, Prof. Ugur Sahin is reported to beneficially own 40,076,320 ordinary shares, representing 15.8% of the company based on 25...
Mega CapBiotechnology
2026-05-15BRTXSCHEDULE 13G/AAuctus Fund Management LLC Reports 9.9% Stake in BioRestorative Therapies, Inc. (BRTX)HIGH
On May 15, 2026, Auctus Fund Management LLC and associated reporting persons (Auctus Fund, LLC, Alfred Sollami, and Louis Posner) filed a Schedule 13G/A for BioRestorative Therapies, Inc. (BRTX). The filing discloses a beneficial ownership of 2,699,470 shares of common stock, representing 9.9% of the company. This hold...
Nano CapBiotechnologyownership +9.90%
2026-05-15BDRXSCHEDULE 13G/AArmistice Capital Increases Stake in Biodexa Pharmaceuticals (BDRX) to 9.99%HIGH
Armistice Capital, LLC and its managing member, Steven Boyd, have filed an amended Schedule 13G (Amendment No. 1) regarding their holdings in Biodexa Pharmaceuticals Plc (BDRX). As of the event date on March 31, 2026, the reporting persons reported beneficial ownership of 187,975 American Depositary Shares, which repre...
Nano CapBiotechnologyownership +9.99%
2026-05-15BHVNSCHEDULE 13G/AJanus Henderson Group plc Decreases Percentage Ownership in Biohaven Ltd. to 11.7%MEDIUM
On May 15, 2026, Janus Henderson Group plc filed a Schedule 13G/A with the SEC, reporting a decrease in its ownership percentage of Biohaven Ltd. (BHVN). As of the event date of March 31, 2026, the firm beneficially owns 17,534,612 common shares, representing an 11.7% stake in the company. This reflects a decrease from...
Small CapBiotechnologyownership-1.00%
Sponsored
Previous Page1415161718192021Next Page